Natdac
Natdac

6.26
Components address viral replication cycles to restrict progress of condition.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Daclatasvir
Reference Brand
Daklinza
Product Origin
Generic Brand
Product Manufacturer
Natco Pharma
Product Form
Tablet
Regulatory Classification
Rx
Primary Category
Antivirals
Product Category
Direct-Acting Antiviral (DAA)
Pharmacological Class
NS5A Inhibitor
Clinical Indications
Manufacturer Description
Intended for chronic hepatitis c to target viral replication and support systemic viral clearance.
Mechanism of Action
Daclatasvir inhibits the HCV NS5A protein, a multifunctional protein required for viral RNA replication and virion assembly. By blocking this protein, it effectively stops the reproduction of the hepatitis C virus.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
12–24 weeks (treatment course)
Contraindications
Concurrent use of potent CYP3A inducers, Hypersensitivity to daclatasvir
Severe Adverse Events
Severe bradycardia, Hepatitis b reactivation, Anaphylaxis — requires immediate medical attention
Common Side Effects
Fatigue, Headache, Nausea
Uncommon Side Effects
Diarrhea, Insomnia, Anemia
Drug Interactions
Alcohol, Amiodarone, Rifampin, St. John's Wort, Ketoconazole
Pregnancy Safety Warnings
FDA Category B: Use only if clearly needed. Breastfeeding: Excretion in milk is unknown.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Storage Guidelines
Store below 30°C.
Related Products
Daklinza, Sovaldi, Harvoni
Information related to Natdac is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
How to order General Medications UK - Diamox Generic